Zhejiang-based active pharmaceutical ingredient and CDMO manufacturer exporting to generic-drug makers abroad.
Zhejiang-based active pharmaceutical ingredient and CDMO manufacturer exporting to generic-drug makers abroad.
In one line: A small Chinese API/CDMO exporter.
Moat: none (scale). Commodity API/CDMO producer competing mainly on cost and regulatory filings.
Headquarters: Taizhou, Zhejiang, China · Employees: 2,026
Size Aurisco Pharmaceutical (605116.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.00B, the 2161st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.57 on 18 Nov 2026.
Performance Over six months the shares fell 23.0%, against -10.6% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 3.1% over the last twelve months (peer median +8.3%); the operating margin is 25.2% (peer median 8.9%).
Valuation It trades at 13.6× forward earnings against a peer median of 20.6× (6th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -21 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.0 points above its cost of capital (5.0% WACC).
Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.67B | CN¥1.69B | CN¥1.47B | CN¥1.26B | CN¥1.00B |
| Revenue growth | — | +15% | +17% | +25% | — |
| Gross profit | CN¥1.01B | CN¥967M | CN¥826M | CN¥671M | CN¥491M |
| EBITDA | n/a | CN¥658M | CN¥474M | CN¥358M | CN¥279M |
| Net income | CN¥317M | CN¥449M | CN¥355M | CN¥289M | CN¥211M |
| Free cash flow | CN¥41.4M | CN¥78.0M | -CN¥204M | CN¥80.2M | -CN¥49.6M |
| Capital expenditure | CN¥367M | CN¥350M | CN¥540M | CN¥305M | CN¥216M |
| Total debt | CN¥1.03B | CN¥1.03B | CN¥1.04B | CN¥271M | CN¥145M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Aurisco Pharmaceutical 605116.SS | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 605116.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.1% | -5.0% | 4th lowest of 21 |
| 6-month return | -23.0% | -10.6% | 6th lowest of 21 |
| Distance from 52-week high | -53.4% | -32.1% | 3rd lowest of 21 |
| Revenue growth (TTM) | +3.1% | +8.3% | 7th lowest of 18 |
| Operating margin | 25.2% | 8.9% | 2nd highest of 18 |
| Forward P/E | 13.6× | 20.6× | 6th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -2.0% | 4.4% | 4th least demanding of 13 |
| Growth delivered (Del g) | +18.7% | +5.6% | 3rd highest of 13 |
| Hurdle (Req g minus delivered) | -20.8 pp | -3.5 pp | least demanding of 13 |
| ROIC minus cost of capital | +8.0 pp | -0.2 pp | 3rd highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |